vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and SunOpta Inc. (STKL). Click either name above to swap in a different company.
SunOpta Inc. is the larger business by last-quarter revenue ($205.4M vs $180.9M, roughly 1.1× AVANOS MEDICAL, INC.). SunOpta Inc. runs the higher net margin — 0.4% vs -0.7%, a 1.1% gap on every dollar of revenue. On growth, SunOpta Inc. posted the faster year-over-year revenue change (16.6% vs 0.7%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $12.1M). Over the past eight quarters, SunOpta Inc.'s revenue compounded faster (7.4% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
SunOpta, Inc. is a multi-national food and mineral company headquartered in Eden Prairie, Minnesota and founded in 1973 in Canada.
AVNS vs STKL — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $205.4M |
| Net Profit | $-1.3M | $816.0K |
| Gross Margin | 47.5% | 12.4% |
| Operating Margin | 1.4% | 3.3% |
| Net Margin | -0.7% | 0.4% |
| Revenue YoY | 0.7% | 16.6% |
| Net Profit YoY | 99.7% | 113.1% |
| EPS (diluted) | $-0.02 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | — | ||
| Q3 25 | $177.8M | $205.4M | ||
| Q2 25 | $175.0M | $191.5M | ||
| Q1 25 | $167.5M | $201.6M | ||
| Q4 24 | $179.6M | $193.9M | ||
| Q3 24 | $170.4M | $175.9M | ||
| Q2 24 | $171.7M | $169.5M | ||
| Q1 24 | $166.1M | $184.4M |
| Q4 25 | $-1.3M | — | ||
| Q3 25 | $-1.4M | $816.0K | ||
| Q2 25 | $-76.8M | $4.4M | ||
| Q1 25 | $6.6M | $4.8M | ||
| Q4 24 | $-397.3M | $-8.7M | ||
| Q3 24 | $4.3M | $-6.2M | ||
| Q2 24 | $1.8M | $-5.3M | ||
| Q1 24 | $-900.0K | $2.9M |
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | 12.4% | ||
| Q2 25 | 52.6% | 14.8% | ||
| Q1 25 | 53.6% | 15.0% | ||
| Q4 24 | 54.6% | 10.9% | ||
| Q3 24 | 54.5% | 13.0% | ||
| Q2 24 | 55.7% | 12.5% | ||
| Q1 24 | 57.1% | 16.8% |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 0.1% | 3.3% | ||
| Q2 25 | -42.6% | 5.5% | ||
| Q1 25 | 6.1% | 5.2% | ||
| Q4 24 | -233.0% | 1.4% | ||
| Q3 24 | 7.0% | 0.5% | ||
| Q2 24 | 3.7% | 1.2% | ||
| Q1 24 | 2.4% | 5.5% |
| Q4 25 | -0.7% | — | ||
| Q3 25 | -0.8% | 0.4% | ||
| Q2 25 | -43.9% | 2.3% | ||
| Q1 25 | 3.9% | 2.4% | ||
| Q4 24 | -221.2% | -4.5% | ||
| Q3 24 | 2.5% | -3.5% | ||
| Q2 24 | 1.0% | -3.1% | ||
| Q1 24 | -0.5% | 1.6% |
| Q4 25 | $-0.02 | — | ||
| Q3 25 | $-0.03 | $0.01 | ||
| Q2 25 | $-1.66 | $0.03 | ||
| Q1 25 | $0.14 | $0.04 | ||
| Q4 24 | $-8.64 | $-0.08 | ||
| Q3 24 | $0.09 | $-0.05 | ||
| Q2 24 | $0.04 | $-0.04 | ||
| Q1 24 | $-0.02 | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $2.2M |
| Total DebtLower is stronger | $90.3M | $250.8M |
| Stockholders' EquityBook value | $778.2M | $162.8M |
| Total Assets | $1.1B | $694.1M |
| Debt / EquityLower = less leverage | 0.12× | 1.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | — | ||
| Q3 25 | $70.5M | $2.2M | ||
| Q2 25 | $90.3M | $2.2M | ||
| Q1 25 | $97.0M | $2.3M | ||
| Q4 24 | $107.7M | $1.6M | ||
| Q3 24 | $89.0M | $2.9M | ||
| Q2 24 | $92.2M | $3.2M | ||
| Q1 24 | $75.8M | $1.5M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | $250.8M | ||
| Q2 25 | $95.7M | $263.3M | ||
| Q1 25 | $98.0M | $260.6M | ||
| Q4 24 | $125.3M | $265.2M | ||
| Q3 24 | $152.6M | $289.9M | ||
| Q2 24 | $164.9M | $303.1M | ||
| Q1 24 | $167.2M | $258.8M |
| Q4 25 | $778.2M | — | ||
| Q3 25 | $778.0M | $162.8M | ||
| Q2 25 | $776.3M | $159.8M | ||
| Q1 25 | $839.4M | $154.8M | ||
| Q4 24 | $828.5M | $148.6M | ||
| Q3 24 | $1.2B | $155.0M | ||
| Q2 24 | $1.2B | $158.8M | ||
| Q1 24 | $1.2B | $163.6M |
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | $694.1M | ||
| Q2 25 | $1.0B | $704.9M | ||
| Q1 25 | $1.1B | $690.7M | ||
| Q4 24 | $1.2B | $668.5M | ||
| Q3 24 | $1.7B | $699.3M | ||
| Q2 24 | $1.7B | $704.7M | ||
| Q1 24 | $1.7B | $671.8M |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | 1.54× | ||
| Q2 25 | 0.12× | 1.65× | ||
| Q1 25 | 0.12× | 1.68× | ||
| Q4 24 | 0.15× | 1.78× | ||
| Q3 24 | 0.12× | 1.87× | ||
| Q2 24 | 0.13× | 1.91× | ||
| Q1 24 | 0.14× | 1.58× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $16.3M |
| Free Cash FlowOCF − Capex | $21.3M | $12.1M |
| FCF MarginFCF / Revenue | 11.8% | 5.9% |
| Capex IntensityCapex / Revenue | 3.8% | 2.1% |
| Cash ConversionOCF / Net Profit | — | 20.03× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $36.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | — | ||
| Q3 25 | $14.0M | $16.3M | ||
| Q2 25 | $6.8M | $-4.5M | ||
| Q1 25 | $25.7M | $22.3M | ||
| Q4 24 | $57.9M | $33.1M | ||
| Q3 24 | $23.0M | $17.2M | ||
| Q2 24 | $27.8M | $-5.6M | ||
| Q1 24 | $-8.0M | $5.3M |
| Q4 25 | $21.3M | — | ||
| Q3 25 | $7.0M | $12.1M | ||
| Q2 25 | $-4.2M | $-9.2M | ||
| Q1 25 | $19.0M | $9.5M | ||
| Q4 24 | $53.1M | $24.0M | ||
| Q3 24 | $20.0M | $11.7M | ||
| Q2 24 | $21.9M | $-15.3M | ||
| Q1 24 | $-12.1M | $-2.3M |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 3.9% | 5.9% | ||
| Q2 25 | -2.4% | -4.8% | ||
| Q1 25 | 11.3% | 4.7% | ||
| Q4 24 | 29.6% | 12.4% | ||
| Q3 24 | 11.7% | 6.6% | ||
| Q2 24 | 12.8% | -9.0% | ||
| Q1 24 | -7.3% | -1.2% |
| Q4 25 | 3.8% | — | ||
| Q3 25 | 3.9% | 2.1% | ||
| Q2 25 | 6.3% | 2.5% | ||
| Q1 25 | 4.0% | 6.3% | ||
| Q4 24 | 2.7% | 4.7% | ||
| Q3 24 | 1.8% | 3.2% | ||
| Q2 24 | 3.4% | 5.7% | ||
| Q1 24 | 2.5% | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | 20.03× | ||
| Q2 25 | — | -1.03× | ||
| Q1 25 | 3.89× | 4.63× | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | 1.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
STKL
| Beverages And Broths | $161.4M | 79% |
| Fruit Snacks | $40.9M | 20% |
| Ingredients | $3.1M | 2% |
